Re-irradiation Cases and Particle Therapy Review
Some cancer patients have previously received radiation therapy and later develop local recurrence or disease progression near the prior treatment area.
In these situations, additional radiation may be difficult.
The main concern is not only the tumor itself, but also the cumulative radiation dose already received by nearby normal tissues and critical organs.
Particle therapy may be reviewed in selected re-irradiation cases because of its ability to concentrate dose more precisely and reduce unnecessary dose to surrounding tissues.
This may be relevant when recurrent disease is located near sensitive structures such as the brain, spinal cord, optic nerves, salivary glands, lungs, liver, bowel, bladder, rectum, or major blood vessels.
However, re-irradiation is complex and requires careful medical review.
Hospitals usually need detailed prior radiation information, including:
- Previous radiation treatment site
- Total dose and fractionation schedule
- Radiation field or treatment plan, if available
- Date of previous radiation therapy
- Recent imaging showing the current disease status
- Current symptoms and performance status
Prior radiation history is important, but the previous radiation field, total dose, nearby organs, and current tumor location must be reviewed before further radiation can be considered.
In some cases, re-irradiation may still be too risky. In other cases, surgery, systemic therapy, supportive care, or local treatment in the patient’s home country may be more appropriate.
For international patients, the practical question is whether a Korean particle therapy center can review the case with sufficient prior treatment information and assess whether re-irradiation may be safe and appropriate.
APIS helps coordinate preliminary communication and document submission to Korean hospitals for selected international re-irradiation cases.
* Final treatment decisions are determined solely by the treating hospitals and physicians.
